Vallon Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2018-01-01
- Employees
- 7
- Market Cap
- -
- Website
- http://www.vallon-pharma.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
Phase 1
Completed
- Conditions
- NarcolepsyADHD
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Vallon Pharmaceuticals, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04647903
- Locations
- 🇺🇸
Vallon Investigational Site, Salt Lake City, Utah, United States
Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
Phase 1
Completed
- Conditions
- NarcolepsyADHD
- Interventions
- Drug: ADAIR 10mg IR capsules
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Vallon Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04232644
- Locations
- 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
News
No news found